 A few months back we discussed why Neurocrine Biosciences stock, a biotech company that develops treatments for neurological and endocrine-related diseases and disorders, looks oversold at 90 levels. Between mid-December 2020 to mid-February 2021, NBIX stock rallied over 30 from 90 to 120. 